Dato-DXd: AstraZeneca and Daiichi Sankyo's Unwavering ADC Pursuit

AstraZeneca and Daiichi Sankyo's investigational antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) has encountered challenges in two pivotal Phase 3 cancer trials.

September 27, 2024

The Radiopharmaceutical Revolution

The radiopharmaceutical industry is witnessing a surge of activity and investment, underscoring the immense potential of these cutting-edge therapies in the fight against cancer.

September 27, 2024

Biotech Funding Rollercoaster: Tracking Valuation Shifts from Seed to IPO

In September, 3 biotechs IPOd on the same day, and their filings revealed an interesting insight: how much money did earlier venture investors make at the IPO?

September 25, 2024

Top 10 BioPharma Market Cap Gains: September 2023 vs. 2024

In the past 12 months, several BioPharma companies experienced substantial gains in market capitalization, driven by continued performance of GLP-1s and improved results in oncology.

September 25, 2024

Biotech IPO Trifecta: A Resurgence of Innovation and Investment

In a rare tripleheader day, three biotechnology companies successfully went public, raising a combined $750 million: Bicara Therapeutics, Zenas BioPharma, and MBX Biosciences.

September 23, 2024

Post-Keytruda: Potential Growth Drivers for Merck

As Keytruda’s LOE approaches in 2028, Merck continues to strengthen its pipeline. Here are some key developments shaping Merck's future:

September 23, 2024

Select Eli Lilly U.S. Patent Expiries

Eli Lilly has seen a growth surge thanks to the success of its GLP-1s, which enjoy patent protection well into the 2030s. The rest of its portfolio is more nuanced - here’s a closer look at key patent expiries in key therapeutic areas:

September 20, 2024

Moderna's Strategic Shift: Paving the Way for Diversification and Profitability

Moderna’s stock moved significantly last week after the company unveiled a reprioritization plan to navigate commercial challenges at its recent R&D day. Here’s a deeper dive into Moderna’s goals to establish a diversified portfolio:

September 20, 2024